LLY
WatchlistEli Lilly and Company
Healthcare · NYSE
$1.06T mkt cap
Brief updated Today
Eli Lilly and Company is a prominent global pharmaceutical firm dedicated to the research, development, and commercialization of human medicines across the world. Its therapeutic offerings include a comprehensive suite of diabetes medications. This encompasses various insulin formulations like Basag
Eli Lilly driven by risk-on rotation
Eli Lilly is a global pharmaceutical firm with strong revenue growth of 55.5% year-over-year. The company's conviction score is 42 out of 100, indicating a watchlist status. With a gross margin of 83.51% and net margin of 34.98%, Eli Lilly's financials are robust. The analyst consensus rating is buy, with a DCF intrinsic value of $455.
Why now
The current risk-on rotation, with a macro signal of +20, makes Eli Lilly compelling right now. The recent 122% year-over-year growth in US Zepbound revenue in Q4 2025 is a significant catalyst.
Key risks
Valuation risk and competitive pipeline risk are significant threats to Eli Lilly's success. The company's P/E ratio of 39.7x indicates a potential valuation risk. A decline in revenue growth or increased competition in the GLP-1 drug market could also invalidate the thesis.
What to watch
Investors should monitor Eli Lilly's revenue growth and margin performance over the next few quarters to confirm the thesis. The company's upcoming earnings reports and pipeline updates will be crucial in assessing the risks and opportunities ahead.
Eli Lilly's Zepbound (tirzepatide) and Mounjaro are leading approved GLP-1 drugs. US Zepbound revenue grew 122% year-over-year in Q4 2025 per Lilly investor relations. Primary pharmaceutical revenue from obesity and diabetes treatment.
⚠Valuation and competitive pipeline risk.
Equities Lower Intraday Ahead of Fed Decision, Major Tech Earnings
The equities market is experiencing intraday losses ahead of the highly anticipated Federal Reserve decision, which could significantly impact market direction and investor sentiment. The decision, coupled with major tech earnings reports, is poised to influence the overall economic outlook.
5d ago
Stock Market Today: Nasdaq, Dow Pare Losses As Fed Stands Pat On Key Rate; Meta Wobbles (Live Coverage)
The Federal Reserve has decided to keep its key interest rate unchanged, leading to a partial recovery in the stock market. This decision has significant implications for the overall monetary policy and market expectations.
5d ago
Fed Decision Exposes Deepening Split Over Rates
The Federal Reserve's latest decision has revealed a deepening divide among policymakers over the future direction of interest rates, potentially impacting monetary policy and market expectations. This split could lead to uncertainty and volatility in financial markets.
5d ago
Equities Lower Intraday Ahead of Fed Decision, Major Tech Earnings
The equities market is experiencing intraday losses ahead of the highly anticipated Federal Reserve decision, which could significantly impact market direction and investor sentiment. The decision, coupled with major tech earnings releases, may lead to substantial market movements.
5d ago
Earnings surprises
+22.7%
2026-04
+9.1%
2026-02
+23.4%
2025-10
+12.7%
2025-08
+2.5%
2025-05
Generated Tue, 04 Aug 2026 06:17:46 GMT by Decifer intelligence engine. For informational purposes only — not investment advice. Decifer Intelligence Hub.